Woodmont Investment Counsel LLC Sells 23,531 Shares of Pfizer Inc. $PFE

Key Points

• Woodmont Investment Counsel LLC reduced its stake in Pfizer Inc. by 8.7% during Q2, now holding 246,450 shares valued at approximately $5.97 million.
• Wall Street analysts have varying projections for Pfizer's future, with target prices ranging from $25.00 to $33.00, maintaining a consensus rating of "Hold."
• Pfizer reported better-than-expected earnings, posting $0.78 EPS for the last quarter, exceeding analysts' estimates of $0.58 and indicating a year-over-year revenue increase of 10.3%.

Woodmont Investment Counsel LLC cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 8.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 246,450 shares of the biopharmaceutical company's stock after selling 23,531 shares during the period. Woodmont Investment Counsel LLC's holdings in Pfizer were worth $5,974,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Capital Advisory Group Advisory Services LLC lifted its holdings in Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after buying an additional 388 shares during the period. Trust Co of the South lifted its holdings in Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after buying an additional 441 shares during the period. Charter Oak Capital Management LLC lifted its holdings in Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after buying an additional 444 shares during the period. Ballentine Partners LLC lifted its holdings in Pfizer by 0.5% in the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock worth $2,260,000 after buying an additional 458 shares during the period. Finally, Members Trust Co lifted its holdings in Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 467 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PFE shares. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Morgan Stanley lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday. Finally, UBS Group restated a "neutral" rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.41.

Pfizer Trading Up 1.1%

NYSE:PFE opened at $27.37 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a market cap of $155.59 billion, a PE ratio of 14.56, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The company has a 50 day simple moving average of $24.67 and a two-hundred day simple moving average of $24.12.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 EPS. The firm's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.